Skip to content

Continuous Tableting Development

ConsiGma® SimpleCT

Making continuous tableting accessible for R&D

ConsiGma CDC with 1 operator

— The R&D Paradigm

Why continuous tableting development feels complex

continuous processing icon

During pharmaceutical R&D, continuous tableting lines require multiple operations to run in parallel, from material feeding and blending to sampling, RTD studies and data alignment. Priorities are different compared to production: rapid experimentation, efficient DoE execution and robust process insight.

Without the right tools, these activities rely heavily on manual coordination, specialist operators and time-consuming workflows that slow down every iteration.


RTD studies are resource-intensive

Spiking, sample collection and time-alignment require precise coordination, and even small misalignments compromise data quality.

Experiments need constant coordination

DoE execution, setpoint changes and sampling must happen simultaneously, requiring multiple operators to stay in sync at every step.

Specialist expertise becomes a bottleneck

When development depends on a small number of experts, every program slows down and capacity becomes the limiting factor.

— Our solution: SimpleCT

From complexity to confidence

SimpleCT is a set of automated development tools integrated into the ConsiGma® continuous tableting platform. It is purpose‑built for R&D — focusing on rapid learning, efficient experimentation and reliable process insight, rather than production complexity.

All tools are designed for contained, repeatable and data aligned operation, supporting a structured and reliable development workflow.


1 operator

To run complex multivariate experiments Tasks that previously required multiple specialists, now handled by a single trained user.

Fewer weeks

Shorter development timelines Even modest reductions in development time have meaningful impact on time-to-market and project value.

1:1

Direct transfer to production Process parameters transfer directly to the ConsiGma® production platform. No re-development.

Overview of the SimpleCT tools

SimpleCT - Assisted DoE

Development steps can be predefined and executed automatically. Instead of manually adjusting dozens of parameters under time pressure, operators move through experimental conditions in a controlled, repeatable way — reducing setup time and minimising the risk of missed steps or incorrect entries.

SimpleCT - Automated Residence Mass Collection

System hold-up assessments and aligned data capture can be triggered at the touch of a button — removing co-ordination overhead and ensuring data integrity across experimental runs.

SimpleCT - Automated Tablet Sampling System

Automated sampling systems collect, bag, label and document samples at high frequency without manual intervention. Tasks that once required multiple operators working closely together can now be performed safely and consistently by a single trained user.

SimpleCT - CAS

Manual spiking operations have historically posed safety and operational concerns. Automated RTD tools ensure accurate timing, consistent spike introduction and full alignment between process data and experimental events — removing a common source of uncertainty in RTD studies.

GEA’s ConsiGma® - a real success story.

One workflow, fewer manual steps

— Key benefits

Faster experiments, safer development

By removing manual coordination and embedding automation into critical development steps, SimpleCT helps R&D teams work faster, generate more reliable data and build confidence in continuous tableting early in the product lifecycle.


01

Faster development and decision making

Run multivariate experiments in fewer runs Reduce manual setpoint changes and coordination Shorten development timelines and speed up progression

02

Higher data quality and process insight

Time aligned process and sampling data Reduced human error during experiments Greater confidence in RTD, mixing behavior and operating windows

03

Lower resource and expertise burden

Complex development activities can often be run by a single operator Reduced dependence on highly specialized personnel More efficient use of limited R&D resources

04

Safer, more contained development

Minimized manual handling of APIs Improved operator safety and containment Lower risk during intensive experimentation

— GEA & Hovione

Built together

Together with Hovione, a leading pharmaceutical CDMO, we developed SimpleCT to address the challenges that R&D scientists actually struggle with in continuous manufacturing development. 

It integrates seamlessly across GEA's ConsiGma® continuous ecosystem, so process knowledge transfers directly to production without the need to start again from scratch.

"SimpleCT allows teams to build confidence in continuous tableting early, creating a stronger foundation for later development stages and commercialisation."

Anthony Tantuccio

Fellow Scientist, Continuous Tableting/Technology Intensification at Hovione

Frequently Asked Questions

What R&D teams most frequently ask when evaluating SimpleCT

Ready to integrate continuous tableting in your R&D?

Pharma solids insight stories

Personal Medication as a result of using continuous manufacturing technologies

Manufacturing medicines for today and the future

As scientists continue to elucidate the genomic basis of diseases such as cancer, it is becoming increasingly possible to develop different drugs for the same condition and target patients with a specific genetic profile.

A New Step Forward - The Future is Continuous

Continuous Innovation: How GEA is Leading the Future of Pharmaceutical Manufacturing

From the first ConsiGma® line in 2004 to the launch of CDC Flex today, GEA has been at the forefront of pharmaceutical innovation.
Continuous innovation is our commitment — to our customers, to the industry, and to a better world.

Contained Compression with NexGen Press

Tailor-Made Containment in the Pharma Industry

The need for the contained handling and processing of pharmaceuticals began to rise significantly about 15 years ago, based on an increased focus on health and safety and the development of highly potent active pharmaceutical ingredients (HPAPIs).

New research highlights exceptional containment performance of the GEA coater

The containment performance of the GEA Coater, described as a “new generation” device capable of both continuous and batch film coating, was assessed during three phases of operation and discussed in a peer-reviewed journal

Receive news from GEA

Stay in touch with GEA innovations and stories by signing up for news from GEA.

Contact us

We are here to help! With just a few details we will be able to respond to your inquiry.